Moberg Pharma AB (FRA:MB8) Asset Impairment Charge : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Moberg Pharma AB Asset Impairment Charge?

Moberg Pharma AB's Asset Impairment Charge for the three months ended in Sep. 2024 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Moberg Pharma AB Asset Impairment Charge Historical Data

The historical data trend for Moberg Pharma AB's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Asset Impairment Charge Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Moberg Pharma AB Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Moberg Pharma AB Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Moberg Pharma AB Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Moberg Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (FRA:MB8) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

MBGPF:USA MOB:Sweden MOBs:UK MB8:Germany

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

Moberg Pharma AB Headlines

No Headlines